172 related articles for article (PubMed ID: 38213297)
1. Measuring Progress in Precision Oncology.
Horak P; Fröhling S
Cancer Discov; 2024 Jan; 14(1):18-19. PubMed ID: 38213297
[TBL] [Abstract][Full Text] [Related]
2. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
3. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
4. Precision Oncology in Pediatric Cancer Surgery.
Lee WG; Kim ES
Surg Oncol Clin N Am; 2024 Apr; 33(2):409-446. PubMed ID: 38401917
[TBL] [Abstract][Full Text] [Related]
5. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.
Chae YK; Pan AP; Davis AA; Patel SP; Carneiro BA; Kurzrock R; Giles FJ
Mol Cancer Ther; 2017 Dec; 16(12):2645-2655. PubMed ID: 29203694
[TBL] [Abstract][Full Text] [Related]
6. Precision Medicine in Pediatric Oncology.
Vo KT; Parsons DW; Seibel NL
Surg Oncol Clin N Am; 2020 Jan; 29(1):63-72. PubMed ID: 31757314
[TBL] [Abstract][Full Text] [Related]
7. [The breakthrough of personalized medicine, new hopes and new challenges].
Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S
Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365
[TBL] [Abstract][Full Text] [Related]
8. Molecular Tumor Boards in Clinical Practice.
Luchini C; Lawlor RT; Milella M; Scarpa A
Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
[TBL] [Abstract][Full Text] [Related]
9. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
10. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
[TBL] [Abstract][Full Text] [Related]
11. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
[TBL] [Abstract][Full Text] [Related]
12. [Precision medicine from experimental to clinical applications in oncology].
Normanno N
Recenti Prog Med; 2015 Dec; 106(12):597-600. PubMed ID: 26780068
[TBL] [Abstract][Full Text] [Related]
13. Proteogenomics drives therapeutic hypothesis generation for precision oncology.
Lei JT; Zhang B
Br J Cancer; 2021 Jul; 125(1):1-3. PubMed ID: 33767418
[TBL] [Abstract][Full Text] [Related]
14. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
15. [Research progress on genome-guided precision oncology and development ideas of antitumor Chinese medicine].
He SF; Wang M
Zhongguo Zhong Yao Za Zhi; 2023 Mar; 48(6):1421-1430. PubMed ID: 37005829
[TBL] [Abstract][Full Text] [Related]
16. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
Nadauld LD; Ford JM; Pritchard D; Brown T
Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
[TBL] [Abstract][Full Text] [Related]
17. Molecular Target and Action Mechanism of Anti-Cancer Agents.
Lee SG
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175963
[TBL] [Abstract][Full Text] [Related]
18. Translational research in oncology--10 years of progress and future prospects.
Doroshow JH; Kummar S
Nat Rev Clin Oncol; 2014 Nov; 11(11):649-62. PubMed ID: 25286976
[TBL] [Abstract][Full Text] [Related]
19. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
20. Precision Medicine in Oncology Pharmacy Practice.
Saadeh C; Bright D; Rustem D
Acta Med Acad; 2019 Apr; 48(1):90-104. PubMed ID: 31264437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
